Portal de investigación
Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes.
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Participantes ajenos a INCLIVA
- Ascaso, Pilar
Grupos y Plataformas de I+D+i
Abstract
BACKGROUND: Diabetic peripheral neuropathy (DPN) is a chronic complication of diabetes mellitus associated with high morbidity and mortality. Major risk factors for DPN include metabolic changes, duration of diabetes, nerve ischaemia and derangements in regeneration and nerve repair programmes. Chemokines have been previously implicated in the pathogenesis of various neuropathies and neuropathic pain processes. The aim of this pilot study was to evaluate the association between the plasma levels of chemokines (CXCL9, CXCL10 and CXCL11) in the presence of DPN in a cohort of type 2 diabetes (T2D) patients. MATERIALS AND METHODS: We studied 73 patients with T2D: 36 with DPN and 37 without DPN. DPN was established through the Semmes-Weinstein test (SW). Plasma levels of circulating chemokines CXCL9, CXCL10 and CXCL11 were determined using DuoSet ELISA kits (Abingdon, UK). RESULTS: We found that levels of CXCL10 were significantly higher in patients with DPN than amongst patients without DPN (57.6 ± 38.3 vs 38.1 ± 33.4 pg/mL, respectively; P = .034). Serum levels of chemokine CXCL9 were also higher amongst patients with DPN but did not reach a statistical significance (188.1 ± 72.7 and 150.4 ± 83.6 pg/mL, respectively, P = .06). CONCLUSIONS: Increased circulating levels of CXCL10 were associated with DPN in T2D patients, suggesting a role of this chemokine in the DPN. Determination of CXCL10 levels could be used as a marker for the early detection and implementation of therapeutic strategies in order to reverse and prevent the DPN.
© 2021 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd.
Datos de la publicación
- ISSN/ISSNe:
- 1368-5031, 1742-1241
- Tipo:
- Article
- Páginas:
- 14302-14302
- DOI:
- 10.1111/ijcp.14302
- PubMed:
- 33930221
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE WILEY-BLACKWELL
Citas Recibidas en Web of Science: 8
Documentos
Filiaciones
Financiación
Proyectos y Estudios Clínicos
Estudio de nuevos mecanismos inflamatorios y angiogénicos asociados a la obesidad grave morbida: papel del eje CXCR3 y los receptores RORs.
Investigador Principal: LAURA PIQUERAS RUIZ
PI15/00082 . INSTITUTO SALUD CARLOS III . 2016
Modulación inmunofarmacológica de la inflamación sistémica asociada a desórdenes metabólicos. Búsqueda de nuevas dianas terapéuticas y síntesis de fármacos novedosos.
Investigador Principal: MARIA JESUS SANZ FERRANDO
SAF2014-57845-R . MINISTERIO ECONOMIA Y COMPETITIVIDAD . 2015
Identificación de nuevos mecanismos implicados en la angiogénesis e inflamación en pacientes obesos. Modulación por ligandos de receptores nucleares constitutivos de androstano.
Investigador Principal: JOSE TOMAS REAL COLLADO
PI18/00209 . INSTITUTO SALUD CARLOS III . 2019
Efecto de la cirugía bariátrica en la inflamación vascular en pacientes con obesidad morbida y diabéticos.
Investigador Principal: LAURA PIQUERAS RUIZ
AICO/2019/250 . CONSELLERIA EDUCACION/INNOVACION,UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL/EMPLEO . 2019
CONTRATOS RIO HORTEGA 2019
Investigador Principal: ANA PALANCA PALANCA
CM19/00027 . INSTITUTO SALUD CARLOS III
Cita
Ascaso P,Palanca A,Martinez S,Sanz MJ,Ascaso JF,Piqueras L,Real JT. Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes. Int. J. Clin. Pract. 2021. 75. (8):p. 14302-14302. IF:3,149. (2).
Peripheral blood levels of CXCL10 are a useful marker for diabetic polyneuropathy in subjects with type 2 diabetes. Ascaso P, Palanca A, Martinez S, Sanz MJ, Ascaso JF, Piqueras L, Real JT. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2021 agosto 01. 75 (8):14302-14302. DOI:10.1111/ijcp.14302. PMID:33930221.
